WOFAPS 2025 8th World Congress of Pediatric Surgery

View Abstract
  1. Home
  2. Congresses
  3. Congress Home
  4. Abstract

Poster - 39

Platelet-rich plasma as an adjuvant therapy to crystallized phenol in the treatment of pediatric pilonidal sinus disease: A prospective randomized controlled trial

Mustafa Azizoğlu 1, Sergey Klyuev 2, Tahsin Onat Kamçı 3, Mehmet Hanifi Okur 4
1 Esenyurt Necmi Kadioglu State Hospital, Dep of Pediatric Surgery, Istinye University, Dep of Stem Cell and Tissue Engineering & 3D Bioprinting, Istanbul, Turkey
2 AO GK MEDSI, Department of Pediatric Surgery, Moscow, Turkey
3 Tatvan State Hospital, Department of Pediatric Surgery, Bitlis, Turkey
4 Department of Pediatric Surgery, Faculty of Medicine Balıkesir Üniversity, Balıkesir, Turkey

Purpose:This study aims to evaluate the safety and efficacy of platelet-rich plasma (PRP) as an adjuvant to crystallized phenol (CP) in treating pediatric pilonidal sinus disease (PSD).

Methods:Eighty-seven patients aged 0-18 were randomly assigned to two groups: the CP group (n=42) and the CP+PRP group (n=45). For those with pilonidal abscesses, incision, drainage, and antibiotics were given. The treatment area was sterilized and numbed with local anesthesia. Hair removal and curettage were performed, followed by the application of crystallized phenol. In CP+PRP group, PRP injections were also administered. The procedure concluded with wound dressing and thorough disinfection.

Results:The CP+PRP group demonstrated significantly shorter healing times (19.4±7.88 days) compared to the CP group (30.7±12.9 days) (p<0.001). The cosmetic score was higher in the CP+PRP group (7.42±1.61) than in the CP group (6.11±1.88, p:0.001). CP+PRP group had lower VAS scores at measured all-time points after applications (p<0.05 for each). Complications were comparable between the groups, with no significant differences in bleeding, infections, or skin burns (p>0.05 for each). No difference was found between groups in terms of total complication rate(p:0.398). The success rate was higher in CP+PRP group (98%; n:44) compared to CP group (86%; n:36) (p:0.039). Recurrence rates were lower in CP+PRP group (2%; n:1) than CP group (14%; n:6) (p:0.039).

Conclusion:The autologous PRP injection in pediatric PSD is safe. The addition of PRP to CP treatment for pediatric PSD significantly improves healing time, cosmetic outcomes, and overall success rates without increasing complication rates. This combined approach offers a promising alternative for effective and efficient treatment of PSD in children.

Keywords: Pediatric pilonidal sinus disease, platelet-rich plasma, crystallized phenol

Close